Pacira Biosciences, INC

Pacira BioSciences announced second quarter 2026 financial results, reporting total revenue of $192.4 million, a 6% year-over-year increase, alongside strategic advancements including the iovera divestiture and EXPAREL reimbursement expansion.

Pacira BioSciences announced an agreement to divest its iovera business to Zimmer Biomet for up to $140 million, including an upfront payment and potential future milestone payments.

Pacira BioSciences stockholders elected three directors and approved an amendment to the 2014 Employee Stock Purchase Plan.

Pacira BioSciences, Inc. announced record-high EXPAREL sales and strong full-year 2025 financial results, driven by its 5x30 strategy and strategic partnerships.

Pacira BioSciences, Inc. announced the appointment of Dr. Samit Hirawat, a veteran biopharmaceutical executive, to its Board of Directors, increasing the board size to 10 members.

Pacira BioSciences announced preliminary unaudited total revenue of $726.4 million for full-year 2025, driven by record-high EXPAREL sales.

Pacira BioSciences, Inc. reported a return to net income in Q3 2025, driven by increased product sales and favorable legal outcomes, alongside strategic acquisitions and pipeline advancements.

Pacira BioSciences reports a net loss for Q2 2025 due to investment impairment and restructuring charges, despite increased revenues.

Pacira BioSciences reports a slight revenue increase in Q1 2025, driven by EXPAREL, and finalizes the acquisition of GQ Bio Therapeutics.

Pacira BioSciences reported its Q3 2024 results, which included a goodwill impairment charge and a patent invalidation, alongside a modest revenue increase.

Pacira BioSciences announced its second quarter 2024 results, showcasing revenue growth and strategic financial activities including a debt offering and share repurchase program.

Pacira BioSciences reported a 4% increase in total revenue for the first quarter of 2024, driven by growth in product sales, while also undergoing a strategic restructuring.

Pacira BioSciences achieved profitability in 2025 with increased product revenues, new strategic partnerships, and significant pipeline advancements, despite legal challenges and an IPR&D impairment.

Pacira BioSciences reports on its 2024 financial performance, strategic initiatives, and ongoing legal and regulatory landscape, highlighting both challenges and opportunities for growth in the non-opioid pain management market.

Pacira BioSciences' 2023 10-K filing highlights its commitment to non-opioid pain management, strategic initiatives for growth, and financial performance.

Jonathan Slonin, Chief Medical Officer of Pacira BioSciences, Inc., sold 3,040 shares of common stock on August 17, 2026 for $23.23 per share.

Pacira BioSciences Director Samit Hirawat was granted 6,405 restricted stock units and 10,891 stock options on June 10, 2026.

Senior Vice President of Finance Lauren Riker sold 6,115 shares of Pacira BioSciences common stock via a 10b5-1 plan.

Pacira BioSciences director Christopher Christie was granted 6,405 restricted stock units and 10,891 stock options.

Director Thomas G. Wiggans was granted 32,675 stock options in Pacira BioSciences, Inc. as part of standard compensation.

Director Alethia Young received a grant of restricted stock units and stock options as part of standard compensation.

Pacira BioSciences, Inc. announces its 2025 Annual Meeting of Stockholders, detailing proposals for director elections, auditor ratification, executive compensation, and stock incentive plan approval.

Pacira BioSciences achieved record revenue of $701 million in 2024 and made significant progress in clinical and regulatory developments.

Pacira BioSciences reaffirms its commitment to enhancing shareholder value through a new $300 million share repurchase program and a focus on operational efficiency and margin expansion.

Pacira BioSciences announces a $300 million share repurchase program and reinforces its confidence in its 5x30 strategic plan to enhance shareholder value.

Pacira BioSciences confirms receipt of director nominations from DOMA Perpetual Capital Management and states that no shareholder action is required at this time.

Pacira BioSciences announces its 2024 Annual Meeting of Stockholders to be held on June 11, 2024, with key proposals including the election of directors, ratification of KPMG as the independent auditor, and advisory vote on executive compensation.

Activist investor DOMA Perpetual Capital Management, holding 7.3% of Pacira BioSciences, has nominated three directors and called for the immediate replacement of CEO Frank Lee and a formal sale process for the company.

Activist investor DOMA Perpetual Capital Management, holding 6.83% of Pacira BioSciences, announced plans to nominate three directors and called for an immediate sale of the company, citing exorbitant executive compensation and general spending.

Doma Perpetual Capital Management, holding a 6.8% stake in Pacira BioSciences, is demanding the company immediately hire bankers to explore a sale, citing management underperformance and excessive spending.

Doma Perpetual Capital Management and affiliated entities have disclosed a 5.7% beneficial ownership stake in Pacira BioSciences, Inc., signaling an intent to influence the company.

State Street Corporation has reported a beneficial ownership of 5.2% in Pacira Biosciences Inc. common stock as of June 30, 2026.

Dimensional Fund Advisors LP has disclosed beneficial ownership of 5.1% of Pacira BioSciences Inc.'s common stock as of March 31, 2026.

The Vanguard Group reported 0% beneficial ownership in Pacira BioSciences Inc. following an internal realignment.

Renaissance Technologies LLC and its parent company have reported a 4.98% beneficial ownership in Pacira BioSciences, Inc. common stock.

Renaissance Technologies LLC and its parent company, Renaissance Technologies Holdings Corporation, have disclosed a 5.34% beneficial ownership stake in Pacira BioSciences, Inc.

Pacer US Small Cap Cash Cows ETF, Pacer US Small Cap Cash Cows Growth Leaders ETF, Pacer Advisors, Inc., and Joe M. Thomson have jointly filed an amended Schedule 13G, disclosing a combined passive beneficial ownership of 1.28% in Pacira BioSciences, Inc.